Announcing the opening of WuXi STA’s first high potency (HP) oral drug product manufacturing facility. This new facility marks a milestone for WuXi STA to further extend its drug product capacity and capabilities to meet the growing demand for HP drug candidate development and manufacturing services.
With this new facility, WuXi STA is well positioned to provide an integrated R&D and manufacturing network for high potency active pharmaceutical ingredients (HPAPI) and drug product from preclinical to commercial manufacturing. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA is committed to further enhancing its integrated platform to enable more healthcare breakthroughs that benefit patients worldwide.
Read more here: https://bit.ly/3SdXpS8